Target family: 1H. Liver X receptor-like receptors (type: nhr)
Target: Liver X receptor-&alpha;

Ligand: 22R-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.3 pEC50
Reference (Journal): An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.
Published in: Nature

Ligand: 24(S), 25-epoxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta.
Published in: Proc Natl Acad Sci USA

Ligand: 24(S), 25-epoxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis.
Published in: Nat Chem Biol

Ligand: 24(S), 25-epoxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway.
Published in: J Biol Chem

Ligand: 24(S)-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.4 pEC50
Reference (Journal): Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway.
Published in: J Biol Chem

Ligand: 27-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.1 pEC50
Reference (Journal): 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells.
Published in: J Biol Chem

Ligand: acetyl-podocarpic dimer (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pEC50
Reference (Journal): A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux.
Published in: J Biol Chem

Ligand: AZ12260493 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.149999618530273 pKi
Reference (Webpage): AZ12260493.

Ligand: desmosterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.539999961853027 pKi
Reference (Journal): Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands.
Published in: J Biol Chem

Ligand: GSK2033 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Discovery of tertiary sulfonamides as potent liver X receptor antagonists.
Published in: J Med Chem

Ligand: GW3965 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.7 pEC50
Reference (Journal): Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.
Published in: J Med Chem

Ligand: IMB-808 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.820000171661377 pEC50
Reference (Journal): Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics.
Published in: Mol Pharmacol

Ligand: L-783483 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.9 pKd
Reference (Journal): A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a).
Published in: Endocrinology

Ligand: paxilline (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.4 pEC50
Reference (Journal): A natural product ligand of the oxysterol receptor, liver X receptor.
Published in: J Pharmacol Exp Ther

Ligand: SR9238 (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity: 6.670000076293945 pIC50
Reference (Journal): A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
Published in: ACS Chem Biol

Ligand: T0901317 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): Role of LXRs in control of lipogenesis.
Published in: Genes Dev